Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › favipiravir

favipiravir

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of favipiravir

6 trials tracked of favipiravir: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 43 citations.

6Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 1 Phase 3 2 Phase 2 3
  1. Phase 3 The Prevent Severe COVID-19 (PRESECO) Study Completed · 43 cited
  2. Phase 4 Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients Completed · 10 cited
  3. Phase 3 Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19 Completed
  4. Phase 2 Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19 Completed
  5. Phase 2 Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19 Completed
  6. Phase 2 Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Favipiravir co-administration with lopinavir-ritonavir increased favipiravir clearance by twofold in COVID-19 patients
Infectious Disease RCT
Favipiravir co-administration with lopinavir-ritonavir increased favipiravir clearance by twofold in COVID-19 patients Trial shows favipiravir and lopinavir-ritonavir do not stop COVID-19
This Phase 2a randomized, double-blind, 2x2 factorial placebo-controlled trial evaluated favipiravir and lopinavir-ritonavir in patients wit…
A new trial reveals that combining favipiravir with lopinavir-ritonavir did not show antiviral activity against the virus in patients with C…
Jul 4, 2026
Favipiravir PEP shows non-significant reduction in SARS-CoV-2 infection among household contacts in Thailand trial
Infectious Disease RCT
Favipiravir PEP shows non-significant reduction in SARS-CoV-2 infection among household contacts in Thailand trial Can a pill protect you after a family member gets COVID?
A phase 2/3 cluster-randomized trial in 168 Thai household contacts of COVID-19 cases compared favipiravir PEP (1600-2000 mg/day for 7 days)…
Taking an antiviral pill after a family member gets COVID might lower infection rates and delay symptoms, though the study's main findings w…
Apr 4, 2026